1:58 PM
 | 
Oct 13, 2017
 |  BioCentury  |  Finance

Sprucely debut

Why Spruce believes $20 million series A could take it to pivotal testing

Spruce Biosciences Inc. emerged from stealth mode on Oct. 12, unveiling a $20 million series A round the company says will fund an ongoing Phase II study for a rare endocrine indication and could propel the program into Phase III testing.

The biotech closed the A round in May 2016; Novo Holdings A/S led the financing, which saw participation from RiverVest Venture Partners.

Spruce’s lead asset, SPR001, is an orally administered small...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >